RLAY
Relay Therapeutics Inc
NASDAQ · Biotechnology
$8.92
+0.77 (+9.45%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 12.13M | 8.15M | 248.56M | 220.69M | 215.28M |
| Net Income | -409,699,433 | -247,602,397 | 61.13M | 45.13M | 45.09M |
| EPS | — | — | — | — | — |
| Profit Margin | -3,374.7% | -3,206.0% | 24.6% | 20.5% | 21.0% |
| Rev Growth | +48.9% | +48.9% | +14.5% | +11.7% | +6.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 543.77M | 477.64M | 487.30M |
| Total Equity | — | — | 884.63M | 867.00M | 902.73M |
| D/E Ratio | — | — | 0.61 | 0.55 | 0.54 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -445,213,188 | -284,013,247 | 104.53M | 96.01M | 91.95M |
| Free Cash Flow | — | — | 79.42M | 41.24M | 69.53M |